ABSTRACT
In 2021, the world experienced the most extensive vaccination campaign to defeat COVID-19. Many cases of idiopathic thrombocytopenia have been reported following injections of SARS-Cov-2 mRNA vaccine. We present the case of a 73-year-old woman with de novo ITP after a first injection of SARS-Cov-2 mRNA vaccine (Moderna vaccine) who experienced a successful rechallenge of SARS-Cov-2 mRNA vaccine (Pfizer vaccine) a few months later.
Subject(s)
COVID-19 , Purpura, Thrombocytopenic, Idiopathic , Vaccines , Aged , COVID-19 Vaccines/adverse effects , Female , Humans , Purpura, Thrombocytopenic, Idiopathic/etiology , RNA, Messenger , SARS-CoV-2 , Vaccines, Synthetic , mRNA VaccinesSubject(s)
COVID-19 , Leukemia, Lymphocytic, Chronic, B-Cell , Lymphoma , Antigens, CD20/genetics , Humans , Immunoglobulins , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Lymphoma/drug therapy , RNA, Messenger , Rituximab/therapeutic useABSTRACT
Complementary tools are warranted to increase the sensitivity of the initial testing for COVID-19. We identified a specific 'sandglass' aspect on the white blood cell scattergram of COVID-19 patients reflecting the presence of circulating plasmacytoid lymphocytes. Patients were dichotomized as COVID-19-positive or -negative based on reverse transcriptase polymerase chain reaction (RT-PCR) and chest computed tomography (CT) scan results. Sensitivity and specificity of the 'sandglass' aspect were 85·9% and 83·5% respectively. The positive predictive value was 94·3%. Our findings provide a non-invasive and simple tool to quickly categorize symptomatic patients as either COVID-19-probable or -improbable especially when RT-PCR and/or chest CT are not rapidly available.